Compare Eli Lilly And Co (LLY) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs NetApp Inc. — how do they compare? Eli Lilly And Co trades at $1,176.32 (market cap $1.04T), while NetApp Inc. trades at $237.28 (market cap $45.38B). The key difference: Eli Lilly And Co is far larger — about 22.9× NetApp Inc.'s market cap, and NetApp Inc. pays the higher dividend (0.9%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and NetApp Inc. for 56 Days on average.
| LLY | NTAP | |
|---|---|---|
Market Cap | $1.04T | $45.38B |
Volume | 3,064,878 | 2,264,311 |
Sector | Health | Technology |
52-Week High | $1.28K | $235.84 |
52-Week Low | $799.57 | $94.11 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $1.09T | $44.34B |
Dividend Yield | 0.59% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
NTAP trades at $235.68, near its 52-week high, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust profitability with a net income margin of 19.19% and ROE of 114.82% for 2025. Recent news highlights strategic AI partnerships with Oracle and Supermicro, enhancing its data infrastructure offerings and market positioning.
The stock presents growth potential driven by AI-driven demand and expanding partnerships, but faces risks from high valuation multiples and competitive pressures. Analyst consensus is mixed with a hold rating bias, though price targets suggest moderate downside from current levels. Investors should weigh strong fundamentals against valuation concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
